Market Overview:
The global rifampin market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of tuberculosis, leprosy, and legionnaire's disease. Additionally, the growing demand for rifampin in Asia Pacific and Middle East & Africa is also contributing to the growth of the market. However, stringent regulatory requirements are restraining the growth of this market. On the basis of type, capsules accounted for a majority share of the global rifampin market in 2017. This can be attributed to their ease-of-use and longer shelf life as compared to other forms such as injections and eye drops.
Product Definition:
Rifampin is an antibiotic that is used to treat a number of infections, including tuberculosis. It works by stopping the growth of bacteria.
Capsule:
Capsule is a small package containing medicine substance. It's main function is to protect the medicines from light, moisture and air. Capsules are made of hard gelatin and are filled with drugs or solutions that need protection. There are different types of capsules such as film-coated, enteric coated, effervescent etc., depending upon the type of drug or solution being carried by capsule.
Injection:
Injection is a medication used for the treatment of tuberculosis. It works by killing the bacteria that causes tuberculosis. In some countries, it is also used for leprosy and syphilis. Rifampin injection (RIFamide) is an injectable form of rifamycin, which has been approved by the U.
Application Insights:
Based on the application, the global market is segmented into tuberculosis, leprosy, legionella disease, and others. The tuberculosis segment dominated the overall market in terms of revenue in 2017. This can be attributed to extensive usage as a front-line therapy for TB across various regions coupled with high prevalence of TB worldwide. According to WHO estimates published in 2018, there were 10 million new cases of TB globally and approximately 1.6 million deaths due to TB annually.
Rifampin is used extensively for treatment purposes against multidrug-resistant (MDR) & extensively drug-resistant (XDR) tuberculosis infections owing to its ability to block mycobacterium growth factor receptors that are essential for bacterial survival inside human cells during antibiotic treatment processes against MDR & XDRTB bacteria respectively.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of tuberculosis, increasing drug-resistant tuberculosis cases, and effective regulatory framework are some of the factors responsible for its largest share. Moreover, high healthcare expenditure and favorable reimbursement policies are also contributing to its large share. In addition, growing interest among individuals in sports & adventure activities is expected to fuel demand for preventive measures such as rifampin over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the coming years owing to rising incidence rates of multi-drug resistant tuberculosis coupled with a rise in government initiatives pertaining towards control & prevention programs especially amongst high-risk groups such as IDUs and HIV patients.
Growth Factors:
- Increasing incidence of tuberculosis (TB) and other infectious diseases that require treatment with rifampin
- Rising demand for rifampin in developing countries, where the prevalence of TB is high
- The increasing use of rifampin in combination therapy regimens for the treatment of various infections
- The growing popularity of rifampin as a prophylactic agent against Mycobacterium avium complex (MAC) infection in patients with advanced HIV/AIDS
- The launch of new, improved formulations and delivery systems for rifampin that make it easier to use and increase its efficacy
Scope Of The Report
Report Attributes
Report Details
Report Title
Rifampin Market Research Report
By Type
Capsule, Injection, Eye Drop
By Application
Tuberculosis, Leprosy, Legionnaire's Disease, Others
By Companies
Sanofi, Wellona Pharma, Mylan, Shenyang Tonglian Group, Fresenius Kabi, Avet Pharmaceuticals Inc., Lannett Company, Lupin Pharmaceutica, Hikma, Shuangding Pharm, Sanofi, Jiangsu Puhua Kesheng, Chengdu Jinhua (Hongyun)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
177
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Rifampin Market Report Segments:
The global Rifampin market is segmented on the basis of:
Types
Capsule, Injection, Eye Drop
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tuberculosis, Leprosy, Legionnaire's Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Wellona Pharma
- Mylan
- Shenyang Tonglian Group
- Fresenius Kabi
- Avet Pharmaceuticals Inc.
- Lannett Company
- Lupin Pharmaceutica
- Hikma
- Shuangding Pharm
- Sanofi
- Jiangsu Puhua Kesheng
- Chengdu Jinhua (Hongyun)
Highlights of The Rifampin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Injection
- Eye Drop
- By Application:
- Tuberculosis
- Leprosy
- Legionnaire's Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rifampin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rifampin is an antibiotic that fights against bacteria. It is used to treat a variety of infections, including tuberculosis (TB), pneumonia, and meningitis. Rifampin can also be used to prevent infection in people who are at high risk for TB, such as those with HIV/AIDS or cancer.
Some of the major companies in the rifampin market are Sanofi, Wellona Pharma, Mylan, Shenyang Tonglian Group, Fresenius Kabi, Avet Pharmaceuticals Inc., Lannett Company, Lupin Pharmaceutica, Hikma, Shuangding Pharm, Sanofi, Jiangsu Puhua Kesheng, Chengdu Jinhua (Hongyun).
The rifampin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rifampin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rifampin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rifampin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rifampin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rifampin Market Size & Forecast, 2018-2028
4.5.1 Rifampin Market Size and Y-o-Y Growth
4.5.2 Rifampin Market Absolute $ Opportunity
Chapter 5 Global Rifampin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Rifampin Market Size Forecast by Type
5.2.1 Capsule
5.2.2 Injection
5.2.3 Eye Drop
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Rifampin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Rifampin Market Size Forecast by Applications
6.2.1 Tuberculosis
6.2.2 Leprosy
6.2.3 Legionnaire's Disease
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rifampin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rifampin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Rifampin Analysis and Forecast
9.1 Introduction
9.2 North America Rifampin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Rifampin Market Size Forecast by Type
9.6.1 Capsule
9.6.2 Injection
9.6.3 Eye Drop
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Rifampin Market Size Forecast by Applications
9.10.1 Tuberculosis
9.10.2 Leprosy
9.10.3 Legionnaire's Disease
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Rifampin Analysis and Forecast
10.1 Introduction
10.2 Europe Rifampin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Rifampin Market Size Forecast by Type
10.6.1 Capsule
10.6.2 Injection
10.6.3 Eye Drop
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Rifampin Market Size Forecast by Applications
10.10.1 Tuberculosis
10.10.2 Leprosy
10.10.3 Legionnaire's Disease
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Rifampin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Rifampin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Rifampin Market Size Forecast by Type
11.6.1 Capsule
11.6.2 Injection
11.6.3 Eye Drop
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Rifampin Market Size Forecast by Applications
11.10.1 Tuberculosis
11.10.2 Leprosy
11.10.3 Legionnaire's Disease
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Rifampin Analysis and Forecast
12.1 Introduction
12.2 Latin America Rifampin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Rifampin Market Size Forecast by Type
12.6.1 Capsule
12.6.2 Injection
12.6.3 Eye Drop
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Rifampin Market Size Forecast by Applications
12.10.1 Tuberculosis
12.10.2 Leprosy
12.10.3 Legionnaire's Disease
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Rifampin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Rifampin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Rifampin Market Size Forecast by Type
13.6.1 Capsule
13.6.2 Injection
13.6.3 Eye Drop
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Rifampin Market Size Forecast by Applications
13.10.1 Tuberculosis
13.10.2 Leprosy
13.10.3 Legionnaire's Disease
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rifampin Market: Competitive Dashboard
14.2 Global Rifampin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Wellona Pharma
14.3.3 Mylan
14.3.4 Shenyang Tonglian Group
14.3.5 Fresenius Kabi
14.3.6 Avet Pharmaceuticals Inc.
14.3.7 Lannett Company
14.3.8 Lupin Pharmaceutica
14.3.9 Hikma
14.3.10 Shuangding Pharm
14.3.11 Sanofi
14.3.12 Jiangsu Puhua Kesheng
14.3.13 Chengdu Jinhua (Hongyun)
